Background {#Sec1}
==========

Adenoviruses (Adv) are nonenveloped, double-stranded DNA viruses that can cause upper and lower respiratory tract infections either in sporadic fashion or as epidemics. Currently, 49 distinct Adv serotypes have been isolated from humans. Adv typically cause mild self-limited respiratory infections. Although Adv can cause a variety of clinical manifestations, in immunocompromised patients, adenovirus infection often leads to fatal outcomes. For example, in immunodeficiency states such as a solid organ or stem cell transplantation, severe adenovirus infection may occur, with mortality up to 80% \[[@CR1]--[@CR4]\].

Outbreaks of adenoviral pneumonia have been occasionally reported in young adult women or military personnel \[[@CR5]--[@CR9]\]. Respiratory tract infection is the leading cause of hospitalization of military trainees in the medical field. A study by the US military showed that 10% of recruits at boot camp were infected with Adv, and 90% of patients with pneumonia were infected with adenovirus \[[@CR10], [@CR11]\]. In 2006, a study by the South Korean military reported that the prevalence of Adv was 61% among military recruits with acute respiratory symptoms \[[@CR12]--[@CR16]\]. Upper respiratory tract infections caused by Adv may also progress to pneumonia. Recently, several case series were reported describing recruits that died in boot camp due to severe adenoviral pneumonia in South Korea since 2012 \[[@CR13], [@CR15]--[@CR17]\]. Even if mortality results or clinical outcome of Adv infection could be affected by selection bias, it has been reported that Adv infection may be severe with a higher incidence of progression to respiratory and multiorgan failure compared to other viral etiologies with the exception of influenza. Thus, some clinical data have been reported regarding predictive factors of respiratory failure associated with Adv infection \[[@CR18], [@CR19]\].

If Adv infection can be diagnosed early, increased monitoring and early applied organ support may improve the clinical outcome of these patients. However, sufficient data on the distinctive characteristics of Adv infections in immunocompetent patients is currently unavailable. We previously observed that adenovirus-positive community-acquired pneumonia (CAP) patients have a high fever and respond differently to antipyretic treatment compared to CAP patients who test positive for other viruses or bacteria. Therefore, the primary goal of this study was to compare the clinical characteristics of Adv- and Non-Adv-positive CAP patients among immunocompetent military personnel and to identify the distinctive characteristics.

Methods {#Sec2}
=======

Study design and definition {#Sec3}
---------------------------

This study was a single-center, retrospective cohort study. We reviewed the medical records of patients who were admitted to the Armed Forces Chuncheon Hospital (Gangwon Province, South Korea, the Referral Hospital for Gangwon Province) for CAP treatment between January of 2014 and December of 2016. Based on the unique characteristics of the Korean military medical system, all military personnel was treated initially in the military hospital despite a lack of diagnostic modalities. Ethical approval was obtained from the Institutional Review Board of the Armed Forces Medical Command (AFMC-16051-IRB-16-041), which waived the need for informed consent because of the retrospective observational nature of the study.

The patients were included in this study when they 1) were admitted for CAP treatment; and 2) had viral polymerase chain reaction (PCR) tests performed on the upper respiratory specimen. The exclusion criteria were as follows: 1) a respiratory viral PCR test was not performed; 2) they had incomplete records; 3) they were immediately transferred to a tertiary hospital for advanced care; and 4) the primary reason for admission was to manage comorbid diseases.

CAP was defined using the definition set forth by the Infectious Society of America/American Thoracic Society Consensus Guidelines \[[@CR20]\]. In short, CAP was diagnosed when the patients had symptoms associated with respiratory tract infections and had new-onset lung infiltration or pleural effusion on chest X-rays or chest computed tomography scans. We defined fever as any temperature greater than or equal to 38 °C recorded by the tympanic route. The body temperatures of all patients were checked every hour at admission day. During the days after admission, the body temperature was often measured within 1 h when patients had a febrile sense or worsening signs of inflammation. We also recorded body temperature at the beginning of antipyretics administration. There is no standardized antipyretic treatment protocol for fever control. In our study, antipyretic therapy was administered upon reaching a body temperature ≥ of 38 °C. The interval of antipyretics administration was according to pharmacodynamics, although we performed additional antipyretics treatment when patients had a fever (two consecutive measurements ≥38 °C) and deterioration of clinical symptoms, including myalgia, general weakness, cough, nasal congestion, or dyspnea within 6 h after antipyretics administration. Responsiveness to antipyretic treatment was classified as follows: a complete response was recorded when a body temperature drop below 38 °C was observed after antipyretics treatment and sustained throughout; a partial response was recorded when a body temperature drop below 38 °C was observed but there was a resurge during observation or a need for additional antipyretics; and no response was recorded when a sustained body temperature above or equal to 38 °C was observed after antipyretics use. Unresponsive to initial antibiotic treatment was defined as observed deterioration as evidenced by worsening of clinical symptoms and signs and/or progression of lesions on radiological studies after 48 to 72 h of initial antibiotics treatment.

Data collection and patient management {#Sec4}
--------------------------------------

All data, including age, sex, smoking history, comorbid conditions, symptoms and clinical signs, initial laboratory and radiological findings, culture results, pneumonia severity index, clinical course, length of hospital stay, and survival outcome were collected from electronic medical records. We evaluated etiologies by sputum, nasopharyngeal or oropharyngeal secretions, blood, and urine using a microbiological culturing approach. Respiratory specimens were typically obtained from self-extracting sputum. When sputum specimens could not be obtained, upper respiratory tract specimens, such as oropharyngeal or nasopharyngeal swabs were used for viral PCR tests. Multiplex real-time PCR was performed using a Real-Q RV Detection kit (BioSewoom, Seoul, Korea) with a Roche Light Cycler 480 II instrument (Roche Diagnostics, Mannheim, Germany). Respiratory viruses included in this test are as follows; adenovirus, rhinovirus, influenza virus A/B, respiratory syncytial virus A/B, metapneumovirus, bocavirus, coronavirus, and parainfluenza virus 1/2/3. All patients were given chest X-rays and/or high resolution computed tomography (HRCT) at the time of our emergency department visit.

Initial antibiotic agents were intravenously administered to all of the patients. Initial antibiotic regimens were followed by adherence to the "Treatment Guidelines for Community-acquired Pneumonia in Korea: An Evidence-based Approach to Appropriate Antimicrobial Therapy" from The Korean Academy of Tuberculosis and Respiratory Diseases \[[@CR21]\]. The antipyretic agents and regimens used in this study were as follows. Propacetamol was intravenously administered at a dose of 1 to 2 g as needed to a maximum of 8 g per day. Acetaminophen was given orally at a dose of 2 tablets (650 mg per tablet) every 8 h to a maximum of 6 tablets per day. Physical cooling methods applied to all febrile patients included external air, ice bag, or water blanket techniques.

Statistical analysis {#Sec5}
--------------------

The data are presented as the means ± standard deviation or as the median \[interquartile range\] for continuous variables and as numbers and percentages for categorical variables. The data were analyzed using Kolmogorov-Smirnov tests for normal distribution. The data were compared using the Mann-Whitney *U*-test or Student's *t*-test for continuous variables and the *χ*^*2*^ or Fisher's exact test for categorical variables. Statistical analyses were performed using SPSS version 23.0 (SPSS Inc., Chicago, IL, USA), and a two-sided *P*-value \< 0.05 was considered to indicate significance.

Results {#Sec6}
=======

Study participants {#Sec7}
------------------

During the study period, there were 445 CAP patients admitted to the Armed Forces Chuncheon Hospital (Fig. [1](#Fig1){ref-type="fig"}). All patients were admitted via the emergency department. Out of 445 cases, 194 cases were excluded. The reasons for exclusion were no respiratory viral PCR test for 170 patients, incomplete data for 20 patients, immediately transferred to the tertiary medical center for two patients, and admission for treatment of underlying diseases for two patients. Two patients who were admitted suspicious combined to underlying disease managed to acute asthma exacerbation. Consequently, 251 patients were enrolled in this study, among whom 67 patients had a positive PCR test for adenovirus (Adv group), while 184 patients had a negative PCR test for adenovirus (Non-Adv group). Among the Non-Adv group patients, no pathogen was detected in 50 patients in all culture assays (unknown pathogen group), while 134 patients were diagnosed with other viruses, bacteria, and combined pathogens (Non-Adv group). Fig. 1Study flow diagram

Comparison of baseline characteristics {#Sec8}
--------------------------------------

Table [1](#Tab1){ref-type="table"} shows the baseline characteristics of the patients in the Adv and Non-Adv groups at admission. The median age was 21.6 years, and all patients were healthy males prior to the onset of illness. The number of current smokers was significantly higher in the Adv group than in the Non-Adv group (22.2% vs. 5.4%, respectively), with recent smokers (\< 30 days) only identified in the Adv group (*n* = 4). A few patients had an underlying disease, such as asthma (*n* = 3), allergic rhinitis (*n* = 3), and pneumothorax (*n* = 2). No differences in the duration of symptoms and the time from symptom onset to admission were observed between the two groups (3.6 ± 1.8 d *vs.*3.2 ± 2.3 d, *P* = 0.224). All patients had clinical symptoms and signs of upper or lower respiratory tract infection. Adv group patients showed more symptomatic instabilities, such as fever, cough, myalgia, headache, and nasal congestion. At admission, initial vital signs and pneumonia severity index (PSI) scores were not significantly different between the two groups. Table 1Comparisons of baseline characteristics at admissionCharacteristicsAdv (*n* = 67)Non-Adv (*n* = 184)Total (*n* = 251)*P* valueAge (year, M\[Q~1~-Q~3~\])21.5 \[20.0--22.0\]21.6 \[20.0--22.0\]21.6 \[20.0--22.0\]0.559Male \[*n* (%)\]67 (100)184 (100)251 (100)NASmoking \[*n* (%)\]\<  0.001 Never smoker45 (67.1)125 (67.9)170 (67.7) Ex-smoker7 (10.4)49 (26.6)56 (22.3) Current smoker15 (22.4)10 (5.4)25 (9.9) Recent smoker (\<  30 days)4 (6.0)0 (0)4 (1.6)BMI (kg/m^2^, *x* ± *s*)23.6 ± 4.323.2 ± 3.323.3 ± 3.60.664Underlying condition \[*n*(%)\]0.575 Asthma3 (4.5)2 (1.1)5 (2.0) Allergic rhinitis2 (3.0)1 (0.5)3 (1.2) Pneumothorax1 (1.5)1 (0.5)2 (0.8)Symptom duration(Time from symptom onset to admission) (d, *x* ± *s*)3.6 ± 1.83.2 ± 2.33.3 ± 2.10.224Symptom and sign \[*n*(%)\] Fever66 (98.5)157 (85.4)223 (88.8)0.021 Cough65 (96.9)157 (85.4)222 (88.4)0.025 Myalgia31 (46.5)56 (30.4)87 (34.7)0.001 Dyspnea(\> mMRC scale II)5 (7.7)11 (6.1)16 (6.4)0.286 Purulent sputum23 (33.8)58 (31.7)81 (32.3)0.335 Headache48 (72.2)96 (52.4)144 (57.4)0.014 Nasal congestion/rhinorrhea44 (65.3)103 (55.8)147 (58.6)0.015Initial vital signs (*x* ± *s*) Systolic blood pressure (mmHg)125.4 ± 12.5124.7 ± 13.1124.9 ± 13.00.598 Heart rate (beats/min)92.5 ± 14.691.2 ± 15.291.7 ± 14.90.335 Respiratory rate (beats/min)18.5 ± 3.218.3 ± 3.818.3 ± 3.6\>  0.999 SpO~2~ on room air (%)97.5 ± 2.396.8 ± 2.097.0 ± 2.10.679Pneumonia severity index (PSI) score M\[Q~1~-Q~3~\]71.0 \[61.0--95.0\]75 \[60.0--96.0\]74 \[60.5--95.9\]0.204Data are shown as mean ± standard deviation, median \[interquartile range\] or number (%)*Adv* Adenovirus, *NA* Not applicable, *mMRC* Modified Medical Research Council, *SpO*~*2*~ Stands for peripheral capillary oxygen

Laboratory and radiological findings between the Adv and non-Adv groups {#Sec9}
-----------------------------------------------------------------------

We compared the laboratory and radiologic findings between the Adv and Non-Adv groups (Table [2](#Tab2){ref-type="table"}). The percentage of patients having leukopenia and thrombocytopenia was higher in the Adv patients *P* \<  0.001), while leukocytosis was more common in the Non-Adv group patients (*P* = 0.035). The levels of infection markers, such as C-reactive protein (CRP) and procalcitonin showed no difference between the two groups. In addition, total bilirubin and creatinine levels showed no significant difference between the two groups. Table 2Comparisons of laboratory and radiologic parameters between Adv and Non-Adv groupsVariablesAdv (*n* = 67)Non-Adv (*n* = 184)Total (*n* = 251)*P* valueResults of laboratory study WBC count (10^9^/L)6.02 ± 4.158.13 ± 4.057.57 ± 4.080.020  Leukopenia (\<  4 × 10^9^/L)21 (31.3)10 (5.4)31 (12.4)\<  0.001  Leukocytosis (\>  10 × 10^9^/L)8 (11.9)52 (28.0)60 (23.9)0.035  Lymphocyte (%)22.15 ± 8.2318.62 ± 9.1519.56 ± 8.900.054  Monocyte (%)12.05 ± 2.7211.02 ± 3.4511.49 ± 3.260.202 Platelet count (10^9^/L)136.3 ± 52.7184.6 ± 63.3171.7 ± 61.2\<  0.001  Thrombocytopenia (\<  150 × 10^9^/L)22 (32.8)17 (9.2)39 (15.5)\<  0.001 Total bilirubin (mg/dl)0.6 ± 0.30.6 ± 0.20.6 ± 0.20.715 Creatinine (mg/dl)0.57 ± 0.140.64 ± 0.140.62 ± 0.140.442 C-reactive protein (mg/dl)5.24 ± 2.946.02 ± 3.116.00 ± 3.050.411 Procalcitonin (ng/ml)0.04 \[0.00--0.08\]0.06 \[0.00--0.10\]0.05 \[0.00--0.08\]0.635Results of etiologic study \[*n*(%)\] Unknown pathogenNA50 (27.2)50 (20.0)NA Viral etiology\[*n*(%)\]\<  0.001  Adv67 (100)NA67 (26.7)NA  Rhinovirus5 (7.5)18 (9.8)23 (9.2)  Influenza A/B virus4 (6.0)22 (12.0)26 (10.4)  HMPV(−)1 (0.5)1 (0.4)  RSV1 (1.5)3 (1.6)4 (1.6)  Parainfluenza virus1 (1.5)3 (1.6)4 (1.6) Bacterial etiology \[*n*(%)\]\<  0.001*S. pneumoniae*3 (4.5)19 (10.3)22 (8.8)*H. influenzae*3 (4.5)12 (6.5)15 (6.0)*M. pneumoniae*5 (7.5)8 (4.3)13 (5.2)*K. pneumoniae*(−)2 (1.1)2 (0.8)Combined etiologies \[*n*(%)\]\<  0.001*S. pneumonia* plus *H.pneumoniae*7 (10.4)14 (7.6)21 (8.4)  Rhinovirus plus *H.pneumoniae*(−)22 (12.0)22 (8.8)  Influenza A/B virus plus *S.pneumoniae*1 (1.5)6 (3.3)7 (2.8)  Influenza A/B virus plus *H.influenzae*(−)2 (1.1)2 (0.8)  RSV plus *H.influenzae*(−)2 (1.1)2 (0.8)Results of radiologic study Dominant pattern \[*n*(%)\]\<  0.001  GGO3(4.5)6 (3.3)9 (3.6)  Consolidation23 (24.3)103 (56.0)126 (50.2)  GGO plus consolidation41 (61.2)75 (40.7)116 (46.2)Distribution \[*n*(%)\]0.015  Unilateral56 (83.5)133 (72.2)189 (75.3)  Bilateral5 (7.5)10 (5.4)15 (6.0)  Multi-lobar (≥ 3 lobes)6 (9.0)41 (22.3)47 (18.7) Pleural effusion \[*n*(%)\]2 (3.0)8 (4.3)10 (4.0)0.483Data are shown as mean ± standard deviation, median \[interquartile range\] or number (%)*NA* Not available, *Adv* Adenovirus, *RSV* Respiratory syncytial virus, *HMPV* Human metapneumovirus, *GGO* Ground glass opacity, *S. pneumoniae Streptococcus pneumoniae*, *H. influenzae Haemophilus influenzae*, *M. pneumoniae Mycoplasma pneumoniae*, *K. pneumoniae Klebsiella pneumoniae*

Possible causative agents were identified in 100% of the Adv group patients and in 72.8% (134/184) of the Non-Adv group patients. In some instances, Adv group patients had coinfections with viruses, such as rhinovirus (*n* = 5), influenza A virus (*n* = 4), respiratory syncytial virus (*n* = 1), and parainfluenza virus (*n* = 1). Bacteria or combined etiologies were more common in the Non-Adv group patients. Rhinovirus (40/184, 21.7%) was most commonly identified as the pathogen in the Non-Adv group patients. The most common bacterial pathogens were *Streptococcus pneumoniae* in the Adv group patients (11/67, 16.4%) and *Haemophilus influenzae* in the Non-Adv group patients (52/184, 28.3%).

The most common radiological feature was ground-glass opacity with consolidation in the Adv group and consolidation in the Non-Adv group (*P* \<  0.001). Unilateral distribution was dominant in both groups (83.5% *vs.*72.7%), however multilobar (≥ 3 lobes) involvement was more common in the Non-Adv group (9.0 *vs.* 22.3%, *P* = 0.015). The presence of pleural effusion was not significantly different between the two groups.

Comparisons of fever and response to antipyretics {#Sec10}
-------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} shows the changes in mean body temperature at admission and during the 7 days after admission between Adv and Non-Adv group patients. In addition, we also compared the fever and response to antipyretic treatment between the patients in the no pathogen group and in the Adv and Non-Adv groups, the results of which are shown in Table [3](#Tab3){ref-type="table"}. In general, Adv group patients had a much longer duration of fever after admission than the Non-Adv patients (3.2 ± 1.6 days *vs.* 1.9 ± 1.2 days, 2.2 ± 1.5 days, *P* = 0.018) and symptom onset (5.8 ± 2.2 days*vs.*3.9 ± 2.5 days, 3.7 ± 2.0 days, *P* = 0.006). To evaluate the degree of fever, we assessed the mean temperature and number of patients to the maximal temperature at admission. The Adv group patients had higher a mean temperature at admission (37.8 ± 0.3 °C*vs.* 37.3 ± 0.3 °C*vs.*37.3 ± 0.2 °C, *P* = 0.005), and more observed instances of a temperature of over 40 and 39 to 40 °C (*P* \<  0.001). The Adv group patients took longer to attain the maximal fall in body temperature than the Non-Adv and unknown pathogen group patients at admission (10.2 ± 5.6 *vs.* 8.0 ± 4.5 *vs.* 8.6 ± 5.5, *P* = 0.015). Fig. 2Comparison to the changes in mean body temperature between the Adv-positive and Adv-negative group patients at admission day (**a**) and within 7 days after admission (**b**). **a** Changes in mean temperature in four hours between the Adv and Non-Adv group patients within 24 h at admission (37.6 ± 0.22 *vs.* 37.1 ± 0.25, *P* = 0.005), **b** Comparison of the mean daily temperature between the Adv and Non-Adv group patients for a week (*P* = 0.156)Table 3Characteristics of fever and response to antipyretics between Adv, Non-Adv, and unknown pathogen groupVariablesAdv group (*n* = 67)Non-Adv group (*n* = 134)Unknown pathogen group (*n* = 50)*P* valueDuration of fever after admission (d,, *x* ± *s*)3.2 ± 1.61.9 ± 1.22.2 ± 1.50.018Duration of fever after symptom onset (d, *x* ± *s*)5.8 ± 2.23.9 ± 2.53.7 ± 2.00.006Mean temperature at admission day (°C, *x* ± *s*)37.8 ± 0.337.3 ± 0.337.3 ± 0.20.005Numbers of patients to maximal temperature at admission \[*n*(%)\]\<  0.001 Over 40 °C10 (14.9)3 (2.2)2 (4.0) 39--40 °C24 (35.8)5 (3.7)3 (6.0)Time of maximal falls in temperature at admission (h, *x* ± *s*)10.2 ± 5.68.0 ± 4.58.6 ± 5.50.015Mean change of temperature at 1 h after administrated antipyretics (°C, *x* ± *s*)1.1 ± 0.71.2 ± 0.61.0 ± 0.70.645Responsiveness to antipyretics at admission \[*n*(%)\]\< 0.001 Complete response30 (44.8)84 (62.7)38 (76.0) Partial response25 (37.3)48 (35.8)12 (24.0) No response12 (17.9)2 (1.5)(−)Data are shown as mean ± standard deviation, median \[interquartile range\] or number (%)

Approximately 18% of Adv group patients had no response to antipyretic treatment, which represented a higher proportion compared with that observed in the Non-Adv or unknown pathogen group patients (*P* \< 0.001). However, the proportion of complete response to antipyretic treatment was comparatively lower in patients in the Adv group than that observed in the Non-Adv or unknown pathogen groups.

Comparison of clinicolaboratory findings between the Adv and non-Adv groups in patients who were unresponsive to initial antibiotics treatment {#Sec11}
----------------------------------------------------------------------------------------------------------------------------------------------

The physician suspected the patient of having atypical pathogens when they had persistent or deteriorating symptoms or signs despite treatment with appropriate empirical antibiotics for 2--3 days. Thus, we compared the clinicolaboratory findings between Adv and Non-Adv group patients who were unresponsive to the initial antibiotics treatment (Table [4](#Tab4){ref-type="table"}). The number of patients who did not a response to initial antibiotics treatment was 47 and 50 in the Adv and Non-Adv groups, respectively. The percentage of patients having leukocytosis and monocytopenia was higher in the Adv patients, although there was no significant difference in white blood cell and platelet counts between the two groups. Leukopenia and thrombocytopenia, which were a showed a significant difference in all study patients, showed no difference in patients with unresponsiveness to initial antibiotics treatment (*P* = 0.720, *P* = 0.733, respectively). Table 4Comparison of clinico-laboratory findings between Adv and Non-Adv patients in whom unresponsive to initial antibiotics treatmentVariablesAdv group (*n* = 47)Non-Adv group (*n* = 50)Total (*n* = 97)*P* valueWBC count (10^9^/L, *x* ± *s*)5.89 ± 3.756.05 ± 3.545.95 ± 3.660.720 Leukopenia (\<  4 × 10^9^/L) \[*n*(%)\]21 (44.7)20 (40.0)41 (42.3)0.435 Leukocytosis (\>  10 × 10^9^/L) \[*n*(%)\]8 (17.0)15 (30.0)23 (23.7)0.015 Lymphocyte (%, *x* ± *s*)22.15 ± 8.2318.62 ± 9.1519.56 ± 8.900.054 Monocyte (%, *x* ± *s*)8.05 ± 3.7211.02 ± 3.459.65 ± 3.560.002 Monocytopenia (\<  150/μl) \[*n*(%)\]8 (17.0)2(4.0)10 (10.3)0.005Platelet count (10^9^/L, *x* ± *s*)128.5 ± 62.5125.5 ± 59.5126.7 ± 61.50.335 Thrombocytopenia (\<  150 × 10^9^/L) \[*n*(%)\]25 (53.2)26 (52.0)51 (52.6)0.736Responsiveness to antipyretics at admission \[*n*(%)\]0.045 Complete response4 (8.5)5 (10.0)9 (9.3) Partial response31 (66.0)40 (80.0)71 (73.2) No response12 (25.5)5 (10.0)17 (17.5)Numbers of maximal temperature at admission \[*n*(%)\]0.003 Over 40 °C8 (17.0)3 (6.0)11 (11.3) 39--40 °C21 (44.7)6 (12.0)27 (27.8)Mean temperature at admission day (°C, *x* ± *s*)37.8 ± 0.337.3 ± 0.237.5 ± 0.20.005Duration of fever after admission (d, *x* ± *s*)3.3 ± 1.52.8 ± 1.63.0 ± 1.50.156Data are shown as mean ± standard deviation or number (%)

A greater number of Adv group patients exhibited no response to antipyretic treatment compared with the Non-Adv group patients (25.5% *vs.*10.0%, *P* = 0.045) as well as the number of patients to reach over 40 °C and 39 to 40 °C (*P* = 0.003). In addition, the Adv group patients had a higher mean temperature at admission than the Non-Adv group patients (37.8 ± 0.3*vs.* 37.3 ± 0.2, *P* = 0.005).

Table [5](#Tab5){ref-type="table"} compares the clinicolaboratory variables between the combined Adv (cAdv), Non-Adv, and only Adv identified pathogen (OAIP) group patients. Compared to the cAdv and Non-Adv patients, more patients in the OAIP group exhibited the following characteristics: were currently smoking; had leukopenia, lymphopenia, monocytopenia, and thrombocytopenia; exhibited a longer duration of fever after symptom onset; had a higher maximal temperature at admission (over 40 °C and 39--40 °C); and exhibited no response to antipyretics at admission. Table 5Comparison of clinico-laboratory variables between combined Adv (cAdv), Non-Adv, and only Adv identified pathogen (OAIP) groupsVariablescAdv group^a^ (*n* = 30)Non-Adv group (*n* = 184)OAIP group^b^ (*n* = 37)*P* valueAge (year, M\[Q~1~-Q~3~\])21.5 \[20.0--22.0\]21.6 \[20.0--22.0\]21.5 \[20.0--22.0\]0.672Smoking \[*n*(%)\]\< 0.001 Never smoker21 (70.0)125 (67.9)24 (64.9) Ex-smoker3 (10.0)49 (26.6)4 (10.8) Current smoker6 (20.0)10 (5.4)9 (24.3) Recent smoker (\<  30 d)2 (6.7)0 (0)2 (5.4)Symptom duration(Time from symptom onset to admission) (d, *x* ± *s*)3.6 ± 1.53.2 ± 2.33.6 ± 2.00.154Symptom and sign \[*n*(%)\] Fever30 (100.0)157 (85.4)36 (97.3)0.062 Cough29 (96.7)157 (85.4)36 (97.3)0.145 Myalgia14 (46.7)56 (30.4)17 (45.9)0.264 Dyspnea (\> mMRC scale II)3 (10.0)11 (6.1)2 (5.4)0.510 Purulent sputum12 (40.0)58 (31.7)11 (29.7)0.126 Headache20 (66.7)96 (52.4)28 (75.7)0.089 Nasal congestion/rhinorrhea20 (66.7)103 (55.8)24 (64.9)0.423WBC count (10^9^/L, *x* ± *s*)7.54 ± 4.288.13 ± 4.054.50 ± 4.020.045 Leukopenia (\<  4 × 10^9^/L) \[*n*(%)\]6 (20.0)10 (5.4)15 (40.5)\< 0.001 Leukocytosis (\>  10 × 10^9^/L) \[*n*(%)\]5 (16.7)52 (28.0)3 (8.1)\< 0.001 Lymphocyte (%, *x* ± *s*)23.84 ± 8.7418.62 ± 9.1520.46 ± 7.720.049 Monocyte (%, *x* ± *s*)14.75 ± 1.6911.02 ± 3.459.35 ± 3.750.002Platelet count (10^9^/L, *x* ± *s*)141.4 ± 45.7184.6 ± 63.3131.2 ± 59.7\< 0.001 Thrombocytopenia (\<  150 × 10^9^/L) \[*n*(%)\]7 (23.3)17 (9.2)15 (40.5)\< 0.001Duration of fever after admission (d, *x* ± *s*)2.9 ± 1.82.0 ± 1.33.5 ± 1.40.121Duration of fever after symptom onset (d, *x* ± *s*)5.6 ± 2.23.8 ± 2.46.0 ± 2.20.015Mean temperature at admission day (°C, *x* ± *s*)37.8 ± 0.337.3 ± 0.337.7 ± 0.40.223Numbers of maximal temperature at admission \[*n*(%)\] Over 40 °C4 (13.3)5 (2.7)6 (16.2)0.016 39--40 °C10 (33.3)8 (4.3)14 (37.8)0.024Responsiveness to antipyretics at admission \[*n*(%)\]\< 0.001 Complete response16 (53.3)122 (66.3)14 (37.8) Partial response12 (40.0)60 (32.6)13 (35.1) No response2 (6.7)2 (1.1)10 (27.1)Data are shown as mean ± standard deviation, median \[interquartile range\] or number (%)*Adv* Adenovirus, *mMRC* Modified Medical Research Council, *CAP* Community-acquired pneumonia^a^cAdv defined that CAP patients with adenovirus combined other virus or bacteria as identified pathogen; ^b^OAIP defined that CAP patients with adenovirus as the only identified pathogen

Comparison of treatment outcome {#Sec12}
-------------------------------

All patients received empirical antibiotic treatment (Table [6](#Tab6){ref-type="table"}) as follows: a 3rd generation cephalosporin plus azithromycin was the most common regimen (*n* = 243, 96.8%), followed by piperacillin/tazobactam plus respiratory quinolone (*n* = 5, 2.0%). The change in antibiotics treatment regimen was more frequent in the Adv group patients than in the Non-Adv patients (70.1% *vs.* 27.2%, *P* = 0.024). The duration of antibiotic treatment was not significantly different between the two groups. In our study, we did not evaluate the administration of cidofovir or adjuvant intravenous immunoglobulin (IVIG). In addition, there were no patients who received mechanical ventilation or extracorporeal membrane oxygenation support. Table 6Comparisons of treatment outcomes between Adv and Non-Adv groupVariablesAdv (*n* = 67)Non-Adv (*n* = 184)Total (*n* = 251)*P* valueInitial antibiotics regimen0.781 3rd cephalosporin plus azithromycin65 (97.0)178 (96.7)243 (96.8) Respiratory quinolone(−)1 (0.5)1 (0.4) Piperacillin/tazobactam plus quinolone1 (1.5)4 (2.2)5 (2.0) Piperacillin/tazobactam(−)1 (0.5)1 (0.4) Carbapenem1 (1.5)(−)1 (0.4)Treatment regimen change (Antibiotics escalation)47 (70.1)50 (27.2)97 (38.6)0.024Duration of antibiotics use, day12.32 ± 2.7611.64 ± 2.8911.85 ± 2.830.114Mean antipyretics dose at admission, gram5.52 \[3.45--6.91\]4.30 \[3.14--6.55\]4.85 \[3.21--6.75\]0.032Duration of antipyretics use, days10.5 ± 2.710.6 ± 3.110.6 ± 3.00.892Adverse event after antipyretics use0.005 Hypotension10 (14.9)4 (2.2)14 (5.6) GI trouble6 (9.0)2 (1.1)8 (3.2) Skin rash1 (1.5)(−)1 (0.4) Elevated liver enzyme4 (6.0)2 (1.1)6 (2.4)Length of hospital stay15.0 ± 2.314.8 ± 2.114.9 ± 2.20.407Time from admission to improvement of discomfort, day4.3 ± 2.82.9 ± 1.83.2 ± 2.00.034In-hospital mortality0 (0)0 (0)0 (0)\>  0.999Data are shown as mean ± standard deviation, median \[interquartile range\] or number (%)*Adv* Adenovirus; *GI* Gastrointestinal

At admission, the mean dose of antipyretics administered was higher in the Adv group patients than in the Non-Adv group patients (5.52 *vs.* 4.30 g, *P* = 0.032), although the overall duration of antipyretics was not significantly different between the two groups. In this study, we identified adverse events after antipyretics administration, such as hypotension, gastrointestinal trouble, skin rash, and elevated liver enzyme, which were commonly observed in the Adv group patients (*P* = 0.005).

The time to overall clinical stabilization from admission was significantly longer in the Adv group patients than in the Non-Adv group patients (4.3 ± 2.8 d *vs.* 2.9 ± 1.8 d, *P* = 0.034). In addition, the length of hospital was not significantly different between the two groups, and no patient died in our study.

Discussion {#Sec13}
==========

In our study, we described the clinical characteristics of Adv-positive community-acquired pneumonia in immunocompetent adult patients. The most important findings were that Adv group patients had a longer duration of fever after symptom onset and admission, a higher mean body temperature at admission, a higher number of patients with a body temperature over 39 °C at admission, a longer duration of the maximal fall in body temperature at admission, and higher rate of no response to antipyretic treatment at admission compared to the Non-Adv group patients. In addition, the instances of leukopenia and thrombocytopenia were greater in the Adv group patients than in the Non-Adv group patients, although in patients who were unresponsive to the initial antibiotics treatment, there was no difference between the two groups. Some epidemiological studies of Adv in South Korea military trainees and personnel have been performed. Yoo et al. \[[@CR15]\] reported that adenovirus was identified in 33.0% of all specimens in febrile respiratory illness (FRI) or pneumonia patients. This study was of reviewed military patients with FRI or pneumonia who were tested for respiratory viruses from October 2014 to May 2016. The proportion of patients with pneumonia and the hospitalization rate did not differ between those with and without adenovirus infection. However, adenovirus-infected patients had a significantly higher risk of requiring intensive care or mechanical ventilator support. These notable findings indicate that adenovirus infection has been occasionally associated with mortality and morbidity with loss in combat strength and an increase in the cost of care.

To date, little data has been reported on the characteristics of fever during Adv infection, especially in immunocompetent patients. In this study, we compared the characteristics of fever in Adv and Non-Adv group patients. The Adv group patients had a longer duration of fever and a higher proportion of peak body temperature than patients infected with other various viral respiratory pathogens or unknown pathogens. Similarly, Ho et al \[[@CR22]\] observed that viral mono-pathogen patients had a higher mean body temperature than bacterial mono-pathogen patients. In addition, dual-pathogen patients, such as *S. pneumoniae* with either influenza A or B, had a higher mean body temperature, although not significantly different from the respective mono-pathogens. However, there is still a lack of detailed data on the specific pathogen-related clinical characteristics, especially fever, in immunocompetent patients. Thus, our data is more likely to aid physicians in determining further diagnostic or therapeutic considerations at the time of admission.

We also evaluated the response to antipyretic treatment between the Adv and Non-Adv groups. Our data showed that the Adv group patients exhibited a higher proportion of individuals with no response to antipyretic treatment compared with the Non-Adv or unknown pathogen group patients. Weisse et al. \[[@CR23]\] evaluated the effect of acetaminophen on fever in bacterial vs. viral infections in 100 children. They concluded that there is no correlation between a fever response to acetaminophen and the etiology of the fever, revealing no usefulness in the response to antipyretic treatment in predicting etiologies of pneumonia. However, our data suggest that there may be a difference in the antipyretic response to Adv compared to other etiologies, and this is the first such data reported for immunocompetent adults.

Our study had several limitations. First, our study was a retrospective design in a single-center, so confounding variables, such as antibiotics regimen or inconsistent timing of antipyretics administration, may have possibly affected the clinical course of fever or response to antipyretic treatment. Second, our study had few reflected unmeasurable variables, such as the genotype of adenovirus, so the difference in the severity of illness between the Adv and Non-Adv groups may have led to the difference in the characteristics of fever and its response to antipyretics. Third, we conducted our study in a military hospital, so our cohort was not representative of the general population, since the military environment has different characteristics, such as living environment, nutrition/immune status, and mode of pathogen spread. Fourth, there was selection bias in that all patients admitted with CAP could not have respiratory PCR tests performed; the examination was limited to an upper respiratory tract, and Adv serotype or viral burden analyses were not performed. Fifth, several potentially relevant pathogens were identified in the study patients. Thus, it is uncertain whether adenovirus was the "leading" pathogen in all patients with multiple pathogens that included adenovirus. Additionally, it is uncertain whether the patients with unknown pathogens were not infected with pathogens.

Conclusions {#Sec14}
===========

To the best of our knowledge, this is the first study to analyze the characteristics of fever and response to antipyretic therapy in immunocompetent adult patients with adenovirus-infected CAP. Patients in the Adv group had some clinical characteristics that were significantly different from those in the Non-Adv group, including a longer duration of fever, a high fever (over 39 °C), and a higher proportion of no response to antipyretic treatment at admission.

Adv

:   Adenovirus

cAdv

:   Combined Adv

CAP

:   Community-acquired pneumonia

CPR

:   C-reactive protein

FRI

:   Febrile respiratory illness

HRCT

:   High resolution computed tomography

OAIP

:   Only Adv identified the pathogen

PCR

:   Polymerase chain reaction
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